Cagrisema combines cagrilintide and semaglutide in a single vial — targeting both the amylin and GLP-1 pathways simultaneously. This dual-mechanism approach is being researched as one of the most effective weight management combinations available.
Product Details
98%+ purity, third-party tested
Certificate of Analysis (COA) included
Fulfilled from the USA
For laboratory research use only (RUO) — not for human consumption